In recent years, the U.S. Food and Drug Administration (FDA) has approved a wave of new therapies, including gene therapies, ...

UPPSALA, SE / ACCESS Newswire / September 17, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) Senzime AB (publ) today announces that ...

Myasthenia gravis often affects younger women, older men and can include a set of confusing symptoms such as slurred speech ...

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

Market is poised for steady growth, projected to expand from USD 2,025.2 million in 2025 to USD 2,828.3 million by 2035, at a ...

Senzime AB ( ($SE:SEZI) ) has shared an announcement. Senzime AB has secured a significant contract with the U.S. Department of Defense to supply ...

Mr. Kamath brings more than 25 years of market access, pricing, and commercial operations experience to Tonix On August 15, 2025, the U.S. Food and Drug Administration approved Tonmya (cyclobenzaprine ...

European pro golfers are wearing virtual reality headsets as part of their training programme. Not to improve their swing, ...

On the FDA’s docket for the back half of September is Merck’s proposed subcutaneous formulation of its blockbuster cancer ...

Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with ...

Positive Phase 1 study showed safety, tolerability and a linear pharmacokinetic: pharmacodynamic: efficacy relationship (1: 1: 1)Planning ...